Evaluates visual and anatomic outcomes in diabetic macular oedema, suggesting effective treatment with fewer injections.
Fig. 1 Full size image In the phase 2/3 PHOTON trial, aflibercept 8 mg at extended dosing intervals maintained similar visual and anatomic improvements with fewer injections and comparable safety to aflibercept 2 mg every 8 weeks in patients with diabetic macular oedema through Week 96 [ 1 ].
No takes yet. Share an insight, caveat, or question.
Diana et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: